2025-07-012026-06-302026-06-30false11430272TAFFS PHARMACY LTD2026-10-16falseiso4217:GBPxbrli:pure114302722025-06-30114302722026-06-30114302722025-07-012026-06-30114302722024-06-30114302722025-06-30114302722024-07-012025-06-3011430272bus:SmallEntities2025-07-012026-06-3011430272bus:AuditExempt-NoAccountantsReport2025-07-012026-06-3011430272bus:FullAccounts2025-07-012026-06-3011430272bus:PrivateLimitedCompanyLtd2025-07-012026-06-3011430272core:WithinOneYear2026-06-3011430272core:AfterOneYear2026-06-3011430272core:WithinOneYear2025-06-3011430272core:AfterOneYear2025-06-3011430272core:ShareCapital2026-06-3011430272core:SharePremium2026-06-3011430272core:RevaluationReserve2026-06-3011430272core:OtherReservesSubtotal2026-06-3011430272core:RetainedEarningsAccumulatedLosses2026-06-3011430272core:ShareCapital2025-06-3011430272core:SharePremium2025-06-3011430272core:RevaluationReserve2025-06-3011430272core:OtherReservesSubtotal2025-06-3011430272core:RetainedEarningsAccumulatedLosses2025-06-3011430272core:LandBuildings2026-06-3011430272core:PlantMachinery2026-06-3011430272core:Vehicles2026-06-3011430272core:FurnitureFittings2026-06-3011430272core:OfficeEquipment2026-06-3011430272core:NetGoodwill2026-06-3011430272core:IntangibleAssetsOtherThanGoodwill2026-06-3011430272core:ListedExchangeTraded2026-06-3011430272core:UnlistedNon-exchangeTraded2026-06-3011430272core:LandBuildings2025-06-3011430272core:PlantMachinery2025-06-3011430272core:Vehicles2025-06-3011430272core:FurnitureFittings2025-06-3011430272core:OfficeEquipment2025-06-3011430272core:NetGoodwill2025-06-3011430272core:IntangibleAssetsOtherThanGoodwill2025-06-3011430272core:ListedExchangeTraded2025-06-3011430272core:UnlistedNon-exchangeTraded2025-06-3011430272core:LandBuildings2025-07-012026-06-3011430272core:PlantMachinery2025-07-012026-06-3011430272core:Vehicles2025-07-012026-06-3011430272core:FurnitureFittings2025-07-012026-06-3011430272core:OfficeEquipment2025-07-012026-06-3011430272core:NetGoodwill2025-07-012026-06-3011430272core:IntangibleAssetsOtherThanGoodwill2025-07-012026-06-3011430272core:ListedExchangeTraded2025-07-012026-06-3011430272core:UnlistedNon-exchangeTraded2025-07-012026-06-3011430272core:MoreThanFiveYears2025-07-012026-06-3011430272core:Non-currentFinancialInstruments2026-06-3011430272core:Non-currentFinancialInstruments2025-06-3011430272dpl:CostSales2025-07-012026-06-3011430272dpl:DistributionCosts2025-07-012026-06-3011430272core:LandBuildings2025-07-012026-06-3011430272core:PlantMachinery2025-07-012026-06-3011430272core:Vehicles2025-07-012026-06-3011430272core:FurnitureFittings2025-07-012026-06-3011430272core:OfficeEquipment2025-07-012026-06-3011430272dpl:AdministrativeExpenses2025-07-012026-06-3011430272core:NetGoodwill2025-07-012026-06-3011430272core:IntangibleAssetsOtherThanGoodwill2025-07-012026-06-3011430272dpl:GroupUndertakings2025-07-012026-06-3011430272dpl:ParticipatingInterests2025-07-012026-06-3011430272dpl:GroupUndertakingscore:ListedExchangeTraded2025-07-012026-06-3011430272core:ListedExchangeTraded2025-07-012026-06-3011430272dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-07-012026-06-3011430272core:UnlistedNon-exchangeTraded2025-07-012026-06-3011430272dpl:CostSales2024-07-012025-06-3011430272dpl:DistributionCosts2024-07-012025-06-3011430272core:LandBuildings2024-07-012025-06-3011430272core:PlantMachinery2024-07-012025-06-3011430272core:Vehicles2024-07-012025-06-3011430272core:FurnitureFittings2024-07-012025-06-3011430272core:OfficeEquipment2024-07-012025-06-3011430272dpl:AdministrativeExpenses2024-07-012025-06-3011430272core:NetGoodwill2024-07-012025-06-3011430272core:IntangibleAssetsOtherThanGoodwill2024-07-012025-06-3011430272dpl:GroupUndertakings2024-07-012025-06-3011430272dpl:ParticipatingInterests2024-07-012025-06-3011430272dpl:GroupUndertakingscore:ListedExchangeTraded2024-07-012025-06-3011430272core:ListedExchangeTraded2024-07-012025-06-3011430272dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-07-012025-06-3011430272core:UnlistedNon-exchangeTraded2024-07-012025-06-3011430272core:NetGoodwill2026-06-3011430272core:IntangibleAssetsOtherThanGoodwill2026-06-3011430272core:LandBuildings2026-06-3011430272core:PlantMachinery2026-06-3011430272core:Vehicles2026-06-3011430272core:FurnitureFittings2026-06-3011430272core:OfficeEquipment2026-06-3011430272core:AfterOneYear2026-06-3011430272core:WithinOneYear2026-06-3011430272core:ListedExchangeTraded2026-06-3011430272core:UnlistedNon-exchangeTraded2026-06-3011430272core:ShareCapital2026-06-3011430272core:SharePremium2026-06-3011430272core:RevaluationReserve2026-06-3011430272core:OtherReservesSubtotal2026-06-3011430272core:RetainedEarningsAccumulatedLosses2026-06-3011430272core:NetGoodwill2025-06-3011430272core:IntangibleAssetsOtherThanGoodwill2025-06-3011430272core:LandBuildings2025-06-3011430272core:PlantMachinery2025-06-3011430272core:Vehicles2025-06-3011430272core:FurnitureFittings2025-06-3011430272core:OfficeEquipment2025-06-3011430272core:AfterOneYear2025-06-3011430272core:WithinOneYear2025-06-3011430272core:ListedExchangeTraded2025-06-3011430272core:UnlistedNon-exchangeTraded2025-06-3011430272core:ShareCapital2025-06-3011430272core:SharePremium2025-06-3011430272core:RevaluationReserve2025-06-3011430272core:OtherReservesSubtotal2025-06-3011430272core:RetainedEarningsAccumulatedLosses2025-06-3011430272core:NetGoodwill2024-06-3011430272core:IntangibleAssetsOtherThanGoodwill2024-06-3011430272core:LandBuildings2024-06-3011430272core:PlantMachinery2024-06-3011430272core:Vehicles2024-06-3011430272core:FurnitureFittings2024-06-3011430272core:OfficeEquipment2024-06-3011430272core:AfterOneYear2024-06-3011430272core:WithinOneYear2024-06-3011430272core:ListedExchangeTraded2024-06-3011430272core:UnlistedNon-exchangeTraded2024-06-3011430272core:ShareCapital2024-06-3011430272core:SharePremium2024-06-3011430272core:RevaluationReserve2024-06-3011430272core:OtherReservesSubtotal2024-06-3011430272core:RetainedEarningsAccumulatedLosses2024-06-3011430272core:AfterOneYear2025-07-012026-06-3011430272core:WithinOneYear2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:CostValuation2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-012026-06-3011430272core:Non-currentFinancialInstrumentscore:CostValuation2026-06-3011430272core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-06-3011430272core:Non-currentFinancialInstrumentscore:CostValuation2025-06-3011430272core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-06-3011430272core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-06-3011430272core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-06-3011430272core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-06-3011430272core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-06-3011430272core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-06-3011430272core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-06-3011430272core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-06-3011430272bus:Director12025-07-012026-06-30114302721bus:Director12025-06-30114302721bus:Director12025-07-012026-06-30114302721bus:Director12026-06-30114302722025-06-30114302722025-07-012026-06-30114302722026-06-30

TAFFS PHARMACY LTD

Registered Number
11430272
(England and Wales)

Unaudited Financial Statements for the Year ended
30 June 2026

TAFFS PHARMACY LTD
Company Information
for the year from 1 July 2025 to 30 June 2026

Director

HAQUE, Taffazzal

Registered Address

70 Wright Street
Hull
HU2 8JD

Registered Number

11430272 (England and Wales)
TAFFS PHARMACY LTD
Balance Sheet as at
30 June 2026

Notes

2026

2025

£

£

£

£

Fixed assets
Intangible assets374,00092,500
Tangible assets4724,488681,679
798,488774,179
Current assets
Stocks541,00040,000
Debtors6,7220,75087,283
Cash at bank and on hand172,945169,120
434,695296,403
Creditors amounts falling due within one year8(337,440)(188,629)
Net current assets (liabilities)97,255107,774
Total assets less current liabilities895,743881,953
Creditors amounts falling due after one year9(564,485)(602,102)
Net assets331,258279,851
Capital and reserves
Called up share capital11
Profit and loss account331,257279,850
Shareholders' funds331,258279,851
The financial statements were approved and authorised for issue by the Director on 16 October 2026, and are signed on its behalf by:
HAQUE, Taffazzal
Director
Registered Company No. 11430272
TAFFS PHARMACY LTD
Notes to the Financial Statements
for the year ended 30 June 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Plant and machinery20
Fixtures and fittings20
Vehicles20
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

20262025
Average number of employees during the year1113
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 July 25185,000185,000
At 30 June 26185,000185,000
Amortisation and impairment
At 01 July 2592,50092,500
Charge for year18,50018,500
At 30 June 26111,000111,000
Net book value
At 30 June 2674,00074,000
At 30 June 2592,50092,500
4.Tangible fixed assets

Land & buildings

Plant & machinery

Vehicles

Office Equipment

Total

£££££
Cost or valuation
At 01 July 25475,937242,8583,45027,960750,205
Additions-34,798-17,48852,286
At 30 June 26475,937277,6563,45045,448802,491
Depreciation and impairment
At 01 July 259,19850,078-9,25068,526
Charge for year--6908,7879,477
At 30 June 269,19850,07869018,03778,003
Net book value
At 30 June 26466,739227,5782,76027,411724,488
At 30 June 25466,739192,7803,45018,710681,679
5.Stocks

2026

2025

££
Finished goods41,00040,000
Total41,00040,000
6.Debtors: amounts due within one year

2026

2025

££
Trade debtors / trade receivables11,35516,034
Other debtors196,61671,249
Prepayments and accrued income139-
Total208,11087,283
7.Debtors: amounts due after one year

2026

2025

££
Other debtors12,640-
Total12,640-
Included within other debtors is an amount receivable from the director of £12,614 (2025: £608 in bank borrowings and overdrafts)
8.Creditors: amounts due within one year

2026

2025

££
Trade creditors / trade payables256,763157,092
Taxation and social security20,66731,537
Other creditors10-
Accrued liabilities and deferred income60,000-
Total337,440188,629
9.Creditors: amounts due after one year

2026

2025

££
Bank borrowings and overdrafts564,485602,102
Total564,485602,102
10.Directors advances, credits and guarantees

Brought forward

Amount advanced

Amount repaid

Carried forward

££££
HAQUE, Taffazzal064,26551,65112,614
Directors Loan Account
064,26551,65112,614
11.Share capital
1 ordinary share
12.Related party transactions
During the year, the Company entered into transactions with related parties, being entities under common control, including Taff's Pharmacy Brigg and The Nova Healthcare Clinic Ltd . At the year end, amounts due from the related parties comprised £105,592 (2025: £2,280) 2026 £105,378 from Taff's Pharmacy Brigg and £214 (2025:£Nil) from The Nova Healthcare Clinic Ltd. These balances are unsecured, interest-free and repayable on demand.